Candel Therapeutics (CADL) Operating Leases (2022 - 2025)

Candel Therapeutics has disclosed Operating Leases across 4 years of filings, most recently posting $1.5 million for Q4 2025.

• Operating Leases for Q4 2025 came in at $1.5 million, up 258.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (up 258.48% YoY), and the FY2025 annual result was $1.5 million, up 258.48% from the prior year.
• Operating Leases came in at $1.5 million for Q4 2025 at Candel Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.8 million in Q1 2022 to a low of $104000.0 in Q2 2025.
• The 4-year median for Operating Leases is $1.2 million (2023), against an average of $1.1 million.
• Peak annual rise in Operating Leases reached 258.48% in 2025, while the deepest fall reached 85.1% in 2025.
• Candel Therapeutics' Operating Leases stood at $1.5 million in 2022, then sank by 34.52% to $973000.0 in 2023, then plunged by 58.17% to $407000.0 in 2024, then surged by 258.48% to $1.5 million in 2025.
• The last three Operating Leases figures came in at $1.5 million (Q4 2025), $1.6 million (Q3 2025), and $104000.0 (Q2 2025), per Business Quant data.